| mgus | R Documentation |
Natural history of 241 subjects with monoclonal gammapothy of undetermined significance (MGUS).
mgus mgus1 mgus2
mgus: A data frame with 241 observations on the following 12 variables.
| id: | subject id |
| age: | age in years |
| sex: | male or female |
| dxyr: | year of diagnosis |
| pcdx: | for subjects who progress to a plasma cell malignancy |
| the subtype of malignancy: multiple myeloma (MM) is the | |
| most common, followed by amyloidosis (AM), macroglobulinemia (MA), | |
| and other lymphprolifative (LP) | |
| pctime: | days from MGUS until diagnosis of a plasma cell malignancy |
| futime: | days from diagnosis to last follow-up |
| death: | 1= follow-up is until death |
| alb: | albumin level at MGUS diagnosis |
| creat: | creatinine at MGUS diagnosis |
| hgb: | hemoglobin at MGUS diagnosis |
| mspike: | size of the monoclonal protien spike at diagnosis |
mgus1: The same data set in start,stop format. Contains the id, age, sex, and laboratory variable described above along with
| start, stop: | sequential intervals of time for each subject |
| status: | =1 if the interval ends in an event |
| event: | the event type |
mgus2: The mgus data, but formatted in the competing risks style. Each subject has three observations, one for time to death, one for time to MM, and one for time to a PC malignancy other than MM. Contains the id, age, sex, and laboratory variable described above along with
| time: | time to event or censoring |
| status: | 1 if the event occured, 0 otherwise |
| event: | death, myeloma, or other |
Plasma cells are responsible for manufacturing immunoglobulins, an important part of the immune defense. At any given time there are estimated to be about 10^6 different immunoglobulins in the circulation at any one time. When a patient has a plasma cell malignancy the distribuion will become dominated by a single isotype, the product of the malignant clone, visible as a spike on a serum protein electrophoresis. Monoclonal gammapothy of undertermined significance (MGUS) is the presence of such a spike, but in a patient with no evidence of overt malignancy. This data set of 241 sequential subjects at Mayo Clinic was the groundbreaking study defining the natural history of such subjects.
Mayo Clinic data courtesy of Dr. Robert Kyle.
R Kyle, Benign monoclonal gammopathy – after 20 to 35 years of follow-up, Mayo Clinic Proc 1993; 68:26-36.